- ￥2223 - 19539
- Biorbyt
- 英国
- orb1819213
- 2026年08月07日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
相关阅读
源叶生物 十万种现货试剂速发，品质稳、品类全，实验不再等！Takara 秋促来袭，提取+反转录+定量套装仅 1200 元abinScience 体内级抗体 全年锁价 低至 ￥1200阿拉丁 22万+ 科研级产品现货速发，品质严控、科研无忧- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
详询
- 保质期：
12 months from date of receipt.
- 英文名：
mTOR inhibitor 9d
- 库存：
99
- 供应商：
Biorbyt
- CAS号：
1144075-38-6
- 规格：
1 mg/5 mg/10 mg/25 mg/50 mg/100 mg/200 mg
| 规格： | 1 mg | 产品价格： | ￥2223.0 |
|---|---|---|---|
| 规格： | 5 mg | 产品价格： | ￥4563.0 |
| 规格： | 10 mg | 产品价格： | ￥6084.0 |
| 规格： | 25 mg | 产品价格： | ￥8307.0 |
| 规格： | 50 mg | 产品价格： | ￥10881.0 |
| 规格： | 100 mg | 产品价格： | ￥14742.0 |
| 规格： | 200 mg | 产品价格： | ￥19539.0 |
描述: The small molecule mTOR inhibitor 9d is a potent dual inhibitor of mTOR and PI3K kinases, exhibiting an mTOR IC50 of 0.31 nM. It is utilized in cancer research, including studies on leukemia and solid tumors, with applications in both in vitro cellular assays and in vivo xenograft models.
别名: mTOR, mTOR inhibitor 9d, 1(2hydroxyethyl)3{4[4(8oxa3azabicyclo[3.2.1]oct3yl)thieno[3,2d]pyrimidin2yl]phenyl}urea, PI3K
靶点: mTOR,PI3K
分子式: C21H23N5O3S
分子量: 425.5
纯度: 98.90% (May vary between batches)
SMILES: N(C(NCCO)=O)C1=CC=C(C2=NC(=C3C(=N2)C=CS3)N4CC5OC(C4)CC5)C=C1
溶解度: DMSO:45 mg/mL (105.76 mM)
研究领域: Pharmacology & Drug Discovery; Cell Biology, Signal Transduction
保存条件: -20°C
备注: For research use only.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验The mammalian target of rapamycin (mTOR) is the catalytic subunit of two multiprotein complexes, mTOR complex-1 (mTORC1) and mTOR complex-2 (mTORC2). Clinically used rapamycin and rapalogs are FKBP12-dependent allosteric inhibitors of mTORC
Expanding Human T Regulatory Cells with the mTOR-Inhibitor Rapamycin
CD4+ CD25+ FOXP3+ T regulatory (Treg) cells are pivotal for the induction and maintenance of peripheral tolerance in both mice and humans. The possibility to use Treg cells for the treatment of T-cell-mediated diseases has recently gained
Development of ATP-Competitive mTOR Inhibitors
mTOR inhibitor rapamycin and structurally related rapalogs have failed to show significant single-agent antitumor efficacy in most types of cancer. This limited clinical success may be due to the inability of the rapalogs to maintain a complete blockade
技术资料暂无技术资料 索取技术资料
